Lab21 to Develop microRNA-Based Colorectal Cancer Diagnostic for IntegraGen | GenomeWeb

British diagnostics service firmLab21 said this week that it has signed a deal to collaborate with diagnostics developer IntegraGen to develop a microRNA-based assay for colorectal cancer.

According to Lab21, it will use its proprietary PCR technology to develop an assay that can detect hsa-miR-31-3p, which is believed to predict response to EGFR inhibitor therapy, such as Erbitux, in KRAS wild-type patients with metastatic colorectal cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.